Geri
Defence Therapeutics Inc. (DTCFF) Fiyatı
DTCFF Hisse Senedi Fiyat Grafiği
DTCFF Kazanmak
Defence Therapeutics Inc.
$0.43
1.16%
$0
Kapanışta: Feb 06, 16:00:00 GMT-5
$0.43
0%
$0
Sonrası Piyasa: Feb 06, 20:00:00 GMT-5
Henüz Veri YokEarnings FAQ
DTCFF'ün son EPS'si beklentilerle karşılaştırıldığında nasıldı?
Defence Therapeutics Inc. DTCFF'ün son çeyrekteki geliri nasıl performans gösterdi?
Defence Therapeutics Inc.'in gelir tahmini nedir?
Defence Therapeutics Inc.'in kazanç kalite puanı nedir?
Defence Therapeutics Inc. kazançlarını ne zaman rapor eder?
Defence Therapeutics Inc.'in beklenen kazançları nelerdir?
Defence Therapeutics Inc. kazanç beklentilerini aştı mı?
Önemli İstatistikler
Önceki Kapanış
$0.43
Açılış fiyatı
$0.4516
Günün Aralığı
$0.435 - $0.4516
52 haftalık aralık
$0.3446 - $1.15
İşlem hacmi
2.8K
Ort.Hacim
33.6K
EPS (TTM)
-0.05
Dividend yield
--
Piyasa Değeri
$23.8M
DEFENCE THERAPEUTICS INC nedir?
Defence Therapeutics, Inc. engages in the research and development of anti-body drug conjugates. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-05-07. The firm is engaged in developing and engineering the antibody drug conjugates (ADC) products using its proprietary platform. Its principal business activity is the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological-/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The core of its therapeutics platform is the ACCUM technology, which enables precision delivery ADCs in their intact form to target cells. The firm is focused on research, development and advancement of the main products using its Accum technology, which include ADC targeting various cancers, Anti-cancer AccuTOX program, Mesenchymal stromal cell-based vaccine (ARM-X) targeting cancer, mRNA vaccination, Cervical cancer vaccine, and Radio-immunoconjugates (RIC) targeting various cancers.
Özellikler
Ticaret Stratejileri
Kaynaklar
© 2025 Finture Development Limited. All rights reserved